Exo Therapeutics Inc. has completed an oversubscribed series B financing for $78 million allowing the small-molecule company to continue developing therapies for treating cancer and inflammation. Exo’s pipeline, created from its Exosight platform, has preclinical candidates that bind exosites, which are distal binding pockets for reprogramming enzyme activity. The exosite drugs include structural and computational biology, protein engineering and DNA-encoded libraries.